Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Sikora

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
HIV Medicine|April 23, 2010
Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growthM J Sikora, J M Rae, M D Johnson, et al.
The Pharmacogenomics Journal|June 16, 2010
High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissuesM J Sikora, J N Thibert, J Salter, et al.
Breast Cancer Research and Treatment|July 22, 2017
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based studyD L Hertz, K M Kidwell, S G Hilsenbeck, et al.
The Pharmacogenomics Journal|May 8, 2009
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsJ M Rae, M J Sikora, N L Henry, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
HIV Medicine|April 23, 2010
Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growthM J Sikora, J M Rae, M D Johnson, et al.
The Pharmacogenomics Journal|June 16, 2010
High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissuesM J Sikora, J N Thibert, J Salter, et al.
Breast Cancer Research and Treatment|July 22, 2017
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based studyD L Hertz, K M Kidwell, S G Hilsenbeck, et al.
The Pharmacogenomics Journal|May 8, 2009
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsJ M Rae, M J Sikora, N L Henry, et al.
Pageof 1